Teva Biosimilar Pipeline Advances with FDA Approval, EMA Filings
Event summary
- Teva received FDA approval for PONLIMSI (denosumab-adet), a biosimilar to Prolia®, for all indications.
- Teva’s biosimilar candidate to Xolair® (omalizumab) has been accepted for review by both the U.S. FDA and the European Medicines Agency (EMA).
- PONLIMSI previously received EMA marketing authorization in November 2025.
- The approvals and filings support Teva’s “Pivot to Growth” strategy, focused on biopharmaceutical expansion.
The big picture
Teva's biosimilar strategy represents a key component of its broader transformation, aiming to offset generic drug pricing pressures and diversify revenue streams. The approval of PONLIMSI and the Xolair® filing demonstrate progress, but biosimilar markets are fiercely competitive, requiring significant investment and execution to achieve market share. The company’s success will depend on navigating complex regulatory landscapes and competing against established players with strong commercial infrastructure.
What we're watching
- Commercialization
- The success of PONLIMSI will hinge on Teva’s ability to secure favorable pricing and market access given Amgen’s established presence with Prolia®.
- Regulatory Risk
- The EMA review of the Xolair® biosimilar will be critical, and any unexpected delays or requests for additional data could impact Teva’s timeline and profitability.
- Pipeline Depth
- Teva’s long-term growth depends on continued success in its biosimilar pipeline, and the company’s ability to advance additional candidates through development and regulatory review.
Related topics